Qiagen is integrating its curated biomedical data into AI agents designed for drug discovery. The company emphasizes that these agents require a foundation of traceable, human-curated information to avoid synthetic results and hallucinations. This approach aims to provide biopharma companies with accurate, reliable data to support their research and development processes.
The Qiagen Discovery Platform utilizes a knowledge base built over 25 years by a team of more than 150 experts, including MDs and PhDs. The platform incorporates the Model Context Protocol and the agentic Discovery Explorer tool. These components are designed to ensure that the information provided by AI agents remains grounded in verifiable, high-quality content.
In May, Qiagen established a partnership with Nvidia Corp. to further develop graph-based AI technologies for the pharmaceutical sector. The company aims to integrate these tools into broader industry ecosystems rather than keeping them in silos. By focusing on traceable data, Qiagen seeks to help customers improve their return on investment through faster and more accurate drug discovery.
